Chest ACCP Member Benefits
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
This Article
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Georgopoulos, D.
Right arrow Articles by Anthonisen, N. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Georgopoulos, D.
Right arrow Articles by Anthonisen, N. R.

Chest, Vol 97, 280-284, Copyright © 1990 by American College of Chest Physicians

ARTICLES

Tolerance to beta 2-agonists in patients with chronic obstructive pulmonary disease

D Georgopoulos, D Wong and NR Anthonisen
Department of Medicine, University of Manitoba, Winnipeg, Canada.

Eleven patients with severe COPD were examined to determine whether tolerance to beta 2-agonists developed after long-term inhalation therapy with these agents. Before the study all patients were on regular treatment with inhaled salbutamol for six months. At the beginning of the study, response of FEV1 to inhaled salbutamol was measured. Dose-response curves were measured after three weeks of treatment with ipratropium bromide and again after a three-week course of inhaled salbutamol. After ipratropium bromide treatment, responses to low doses of salbutamol tended to be larger than after salbutamol treatment, but differences were not significant. Three hours after the last inhalation of salbutamol the FEV1 was lower on days 1 and 42 than on day 21. We conclude that long-term inhalation therapy with beta 2- agonists in patients with COPD decreases the duration of the bronchodilation produced by the same agents but does not affect the peak response.


This article has been cited by other articles:


Home page
 Am. J. Respir. Crit. Care Med.Home page
T. NIU, J. J. ROGUS, C. CHEN, B. WANG, J. YANG, Z. FANG, S. T. WEISS, and X. XU
Familial Aggregation of Bronchodilator Response . A Community-Based Study
Am. J. Respir. Crit. Care Med., November 1, 2000; 162(5): 1833 - 1837.
[Abstract] [Full Text]

Home page
 J. Pharmacol. Exp. Ther.Home page
D. E. Wachsman, J. P. Kavaler, I. P. Sugár, E. N. Schachter, W. Gonsiorek, and S. Maayani
Kinetic Studies of Desensitization and Resensitization of the Relaxation Response to Beta-2 Adrenoceptor Agonists in Isolated Guinea Pig Trachea
J. Pharmacol. Exp. Ther., January 1, 1997; 280(1): 332 - 345.
[Abstract] [Full Text]

Home page
 NEJMHome page
H. S. Nelson
{beta}-Adrenergic Bronchodilators
N. Engl. J. Med., August 24, 1995; 333(8): 499 - 507.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1990 by the American College of Chest Physicians.